Grace Therapeutics, Inc. (GRCE)
EBITDA Growth
-44.49%
TTM · Period ending:
GRCE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-44.49%period ending
Latest reported-44.49%period ending
GRCE TTM EBITDA YoY % (-44.70% → -44.49%)
Year-over-year change
High-resolution chart · PNG
GRCE ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -44.4897% | |
| 39.5486% | |
| 32.1269% | |
| 17.9579% | |
| 1.6837% | |
| -41.103% | |
| -30.1682% | |
| -11.0565% | |
| 11.4493% | |
| 32.1026% | |
| 26.3484% | |
| 17.7539% | |
| 4.2887% | |
| -10.8581% | |
| 5.6568% | |
| -2.5052% | |
| -0.2156% | |
| 13.1724% | |
| -211.9727% | |
| -267.1839% | |
| -535.8012% | |
| -390.5733% | |
| 140.0582% | |
| 129.1614% | |
| 91.7209% | |
| 87.2679% | |
| -73.7492% | |
| -38.5007% | |
| -127.3087% | |
| -160.9055% | |
| -199.4194% | |
| -340.6767% | |
| -197.1436% | |
| -88.4189% | |
| -37.5234% | |
| -35.5154% | |
| -51.9582% | |
| -761.2429% | |
| -176.9111% | |
| -689.0546% | |
| -9,291.6226% | |
| 114.0048% | |
| 70.3364% | |
| 105.5613% | |
| 99.5535% | |
| 23.5919% | |
| 16.0701% | |
| -47.7715% | |
| -41.4909% | |
| -14.267% | |
| 0.9664% | |
| -0.8476% | |
| -9.3725% | |
| -59.24% | |
| -117.8391% | |
| -144.5856% | |
| -194.6655% | |
| -149.6043% | |
| -86.4034% | |
| -62.3648% | |
| -44.7034% |